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Abstract 35 
Low density lipoprotein receptors (LDLR) are appealing cell surface targets in drug 
delivery, as they are expressed in the blood-brain barrier (BBB) endothelium and are 
able to mediate transcytosis of functionalized drugs for molecular therapies of the 
central nervous system (CNS). On the other hand, brain-targeted drug delivery is 
currently limited, among others, by the poor availability of biocompatible vehicles, as 40 
most of the nanoparticles under development as drug carriers pose severe toxicity 
issues. In this context, protein nanoparticles offer functional versatility, easy and cost-
effective bioproduction and full biocompatibility. In this study, we have designed and 
characterized several chimerical proteins containing different LDLR ligands, regarding 
their ability to bind and internalize target cells and to self-organize as viral mimetic 45 
agents. While the self-assembling of LDLR-binding proteins as nanoparticles positively 
influences cell penetration in vitro, the nano-particulate architecture might be not 
favouring BBB crossing in vivo. These findings are discussed in the context of the use 
of nanostructured materials as vehicles for the systemic treatment of CNS diseases. 
 50 
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Introduction 
 
Cell-targeted drug delivery and personalized medicines strongly push towards the 55 
development of biocompatible materials adapted to deliver cargo drugs to specific cell 
types. A critical point in such design process is the selection of intrinsically non-toxic 
materials, which while keeping high structural and functional tunability would not induce 
side effects upon administration. Because of their biodegradability, biocompatibility and 
functional and structural plasticity, proteins are highly convenient materials to construct 60 
carriers for the delivery of both conventional and emerging drugs (Lohcharoenkal et al., 
2014). On the other hand, drug vehicles, apart from exhibiting powerful targeting 
properties, should overcome the sequential biological barriers encountered previous to 
reaching the right cell compartment in the target organ. This is compulsory when 
targeting the central nervous system (CNS) that is protected by the blood-brain barrier 65 
(BBB) and by the blood spinal cord barrier. Since in a therapeutic context, local 
administration into brain is not desirable because its invasiveness (Lockman et al., 
2002), systemic administration is mandatory and empowering drugs to cross the BBB 
has become a major issue in current pharmacology and nanomedicine (Pardridge, 
2010). BBB tightly controls the access of molecules and drugs to brain, either by 70 
paracelullar or transcellular pathways, by using both functional and structural elements 
addressed to maintain brain homeostasis (Barbu et al., 2009). Hydrophilic and cationic 
small molecules show some spontaneous penetrability. However, usual chemical drugs 
and therapeutic proteins cannot cross the BBB or are targets for the efflux pumps 
acting in the BBB. A nanoparticulate organization of vehicles used for systemic drug 75 
delivery increases drug stability and circulation time (Cespedes et al., 2014), what 
preventing renal filtration offers potential for sustained release of the cargo. Although 
these and other properties of nanostructured materials are highly desirable, 
paracelullar penetration of nanoparticles targeted to the central nervous system (CNS) 
is assumed to be especially problematical. Functionalization with ligands of hormone 80 
receptors or transporters for transcytosis is then mandatory despite the unexpected 
BBB-crossing activities exhibited by a few polymers used for nanoparticle fabrication 
and coating (eg polysorbate 80 and poly-[ethylene glycol-co-hexadecyl]-cyanoacrylate 
(Kim et al., 2007; Kreuter et al., 2002a)).  
 85 
A catalogue of potential BBB-crossing peptides and proteins for functionalization is 
available (Van et al., 2012) (http://brainpeps.ugent.be). Among them, ligands binding 
transferrin, insulin and low density lipoprotein receptors (LDLR) have been especially 
appealing because of their transcytotic properties. LDLR, in particular, are of additional 
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interest as they are overexpresed in several human conditions including lung, stomach 90 
and cervical cancers. Several LDRL protein ligands, namely ApoB (Spencer and 
Verma, 2007b); ApoE (Re et al., 2011; Wagner et al., 2012) and Apo A-I (Fioravanti  et 
al., 2012; Kratzer et al., 2007), have been already used to functionalize diverse types of 
drugs and nanoparticles to allow or enhance BBB crossing. Others, such as Kunitz-
derived peptides (Angiopeps), presented in plain protein-drug complexes, have entered 95 
clinical trials addressed to brain tumors. (Kurzrock et al., 2012). 
(http://clinicaltrials.gov/ct2/show/NCT01480583?term=ANG1005&rank=6). Although 
several of these LDLR ligands have proved to be promising, the ideal architecture for 
the drug-ligand complex to effectively cross the BBB and reach the brain remains to be 
elucidated. In particular, whether the ligand would be more effective when 100 
functionalizing a nanostructured vehicle than when applied in plain ligand-drug 
complexes remains unsolved, being a critical issue that needs further investigation 
(Juillerat-Jeanneret, 2008). 
 
In the present study we have selected several known peptidic LDLR ligands and 105 
explored them as BBB crossers, in protein-only materials under several presentations. 
Some of these constructs self-organize as nanoparticulate materials while others 
remain in monomeric, unassembled forms. The in vitro and in vivo analyses of cell 
penetrability, biodistribution and brain targeting provide new concepts about the BBB 
crossing properties of functional protein nanoparticles, and suggest divergent diffusion 110 
properties when acting in cell culture and upon systemic administration.   
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Materials and methods 
Protein production and purification 
Vectors derived from pET-22a and harboring angiopep-2-GFP-H6, seq-1-GFP-H6 and 
apoB-GFP-H6 gene sequences had been designed in-house and constructed by 115 
Genscript. These plasmids were transformed into Escherichia coli BL21 (DE3) and 
positive clones selected in presence of 100 µg/ml ampicillin. Transformed bacteria 
were cultured in 750 ml LB (Luria Bertani, Conda Cat. 1551.00) medium in presence of 
100 µg/ml ampicillin at 37 °C until OD550=0.5, and incubated further overnight at 28 °C 
with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) to trigger protein production. 120 
Bacteria were harvested through centrifugation and resuspended in Tris buffer (20 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 10 mM Imidazol) in the presence of EDTA-free 
protease inhibitor (Complete EDTA-Free; Roche).Then, cells were disrupted by a 
French press (Thermo FA-078A) at 1100 psi, and the soluble fraction separated from 
the mixture by centrifugation at 15,000 g for 30 min. The insoluble fraction from ApoB-125 
GFP-H6 was stored at -80°C for further use. 
 
All proteins were purified by His affinity chromatography in an ÄKTA purifier FPLC (GE 
healthcare). After filtering the soluble fraction, samples were loaded onto HiTrap 
Chelating HP 1 ml columns (GE healthcare), washed with Tris wash buffer (20 mM 130 
Tris-HCl pH 8.0, 500 mM NaCl, 10 mM Imidazol) and eluted with Tris elution buffer (20 
mM Tris-HCl pH 8.0, 500 mM NaCl, 500 mM Imidazol). After purification, 
corresponding fractions were collected and then dialyzed against carbonate buffer (166 
mM NaHCO3, pH 7.4) overnight at 4°C. Proteins were characterized by mass 
spectrometry and quantified by Bradford assay. Some of these activities were 135 
technically supported by the Protein Production Platform CIBER-BBN/UAB 
(http://www.ciber-bbn.es/en/programas/89-plataforma-de-produccion-de-proteinas-
ppp). 
 
Protein purification from inclusion bodies   140 
The pellet of ApoB-GFP-H6 IBs was washed with water twice, and resuspended with 
solubilizing buffer (40 mM Tris with 0.2 % N-lauroyl sacosine, pH 8.0) in a ratio 1:40 
and incubated for 24 h at room temperature. After that, the sample was centrifuged at 
15000 g for 30 min. Resuspended soluble protein from IBs was purified as described 
above with prior N-lauroyl sarcosine removal by using a Hitrap QFF ion exchange 145 
column (GE healthcare). 
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Cell culture and flow cytometry  150 
HeLa (ATCC-CCL-2) cells were cultured in DMEM (GIBCO, Rockville, MD) 
supplemented with 10 % Fetal Calf Serum (GIBCO) at 37 °C and 5 % CO2. Human 
umbilical vein endothelial cells (HUVEC) were maintained in M199 (Invitrogen) with 5 
% Fetal Calf Serum (FBS) and 1.2 mM L-Glutamine, at 37 °C. Cells were incubated 
with recombinant proteins (1 µM and 9 µM) for 24 h and further treated with 1 mg/ml 155 
trypsin for 15 min to remove non-internalized protein. Then cells were collected and 
analyzed on a FACSCanto system (Becton Dickinson), using a 15 W air-cooled argon-
ion laser at 488 nm excitation. GFP fluorescence emission was measured with detector 
D (530/30 nm band pass filter). In endosomal escape of proteins experiment, 
chloroquine was added 4 h before adding protein to the cell, and reach a final 160 
concentration of 100 µM, after that, cells were incubated with chloroquine and 
recombinant protein for 24 h, and then treated with the same procedure.       
       
Transmission electron microscopy (TEM)  
Purified proteins were diluted to 0.2 mg/ml in dialysis buffer (166 mM NaHCO3, pH 7.4), 165 
deposited onto carbon-coated grids for 2 min, stained with uranyl acetate and observed 
in a Hitachi H-7000 transmission electron microscope. 
 
Confocal microscopy 
HeLa cells were seeded on Mat-Teck culture dishes (Mat Teck Corp., Ashland, MA, 170 
USA), and after 24 h, 2 µM of protein was added to cell culture, then it was incubated 
for another 24 h. The nucleus was stained with Hoechst 33342 (0.2 g/ml, Molecular 
Probes) and plasma membrane was stained with CellMask™ Deep Red (2.5 g/ml, 
Molecular Probes) for 5 min in darkness. Later, cells were washed with PBS (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany). Stained cells were examined using TCS-175 
SP5 confocal laser scanning microscope (Leica Microsystems, Heidelberg, Germany) 
with a Plan Apo 63×/1.4 (oil HC × PL APO l blue) objective. Hoechst 33342 was 
excited by a blue diode (405 nm) and detected at the 415-460 nm range. GFP proteins 
were excited by an Ar laser (488 nm) and detected at the 525-545 nm range. CellMask 
was excited by a HeNe laser (633 nm) and detected at the 650-775 nm range. Z-series 180 
were collected at 0.5 m intervals. 
 
Fluorescence determination and dynamic light scattering (DLS) 
All proteins were diluted to 400 μg/ml; then GFP fluorescence was determined by Cary 
Eclipse Fluorescence Spectrophotometer (Variant) at detection wavelength of 510 nm, 185 
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by using an excitation wavelength of 450 nm. Volume size distribution of nanoparticles 
and monomeric GFP fusions were determined by dynamic light scattering at 633 nm 
(Zetasizer Nano ZS, Malvern Instruments Limited, Malvern, UK). 
 
Cell permeability analysis 190 
Permeability studies were performed at the USEF Drug Screening Platform 
(http://www.usc.es/en/investigacion/riaidt/usef). Briefly, CaCo2 cells were cultured in 
DMEM high in glucose supplemented with 10 % FBS, 1 % nonessential amino acids 
(100x), 1 % L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin 95 % air and 5 % 
CO2 and at 37 °C. The cells (CaCo2, passage 65) were seeded in the apical 195 
compartment of a sterile 6-well transwell at a density of 250,000 cells / well in 1.5 ml of 
medium and 2.5 ml of fresh medium was then added to the basal compartment. Cells 
were maintained in this medium for 21 days until complete differentiation (renewing the 
medium every 2 days). After this time, the medium was changed to HBSS (0.9 mM 
CaCl2, 0.5 mM MgCl2, and 20 mM HEPES, pH 7.4). 200 
 
Transepithelial resistance (TEER) measurement was conducted using a Millipore 
epithelial voltmeter (Millicell-ERS) in a 6 well traswell (Costar). After adding HBSS in 
both compartments, samples were added in the apical part at different time intervals (0, 
30, 60 sec and 20 min) for TEER measurements. To determine protein transport 205 
through Caco2, the amount of transported protein was determined by the 
measurements of fluorescence in basal compartment over time. Experiments were 
performed in triplicate. Data were expressed as % of initial TEER. The % is calculated 
based on the formula: % Initial TEER = (TO / TI) * 100; where TO is the TEER 
observed in the wells with the samples under study and TI is the TEER observed 210 
before addition of samples. The transport was assessed by the apparent permeability 
(cm / sec), the amount is represented as protein against time and the slope of the 
linear fit (Δamount /Δtime) was used to calculate the apparent permeability (Papp) by 
the formula: Papp = (Δamount / Δtime) / (AxC0); where A is the area of the growth 
surface (4.71 cm2) and C0 is the initial concentration (M) present in the apical 215 
compartment. 
 
In vivo model and biodistribution analyses   
Five-week-old female Swiss nu/nu mice weighing between 18 and 20 g (Charles River, 
L-Abreslle, France) and maintained in SPF conditions, were used for in vivo studies. All 220 
the in vivo procedures were approved by the Hospital de Sant Pau Animal Ethics 
Committee and performed according to EC directives. Proteins were injected 
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intravenously at a dose of 500 µg/mouse (n=3 mice), control mice was injected with 
NaHCO3 buffer. At 5, 15, 30 min, 1 h and 2 h after injection, mice were anesthetized 
with isofluorane and whole body fluorescence was monitored using IVIS spectrum 225 
equipment (Xenogen, France). After that, mice were sacrificed and brain, kidney, lung 
and liver collected and examined separately at 30 min and 2 h for GFP fluorescence in 
an IVIS Spectrum. The ex vivo fluorescent recording of the brain was performed 
sequentially, first measuring the emission from whole brain and then of sagittal sections 
to achieve a complete fluorescent signal characterization.  230 
 
Statistical analyses   
Data were analyzed using one-way ANOVA and post hoc Tukey tests. 
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Results  
Three chimerical genes were constructed to produce LDLR-binding recombinant 235 
proteins (Table 1), based on the following modular organization; from N- to C-termini, 
ligand, linker, EGFP and H6 tail (Figure 1A). Such organization had been previously 
proved useful in promoting the spontaneous formation of highly stable fluorescent 
protein nanoparticles, provided a sufficient positive electrostatic charge is present at 
the N terminus of the whole fusion (Cespedes et al., 2014; Unzueta et al., 2012). 240 
Angiopep-2 and Seq-1 fusions were produced in E. coli as fully soluble versions while 
ApoB-GFP-H6 obtained from the soluble cell fraction was partially proteolized. In fact, 
protein sequencing by Edman degradation procedure of the soluble protein form 
revealed loss of the amino-terminal 34-mer peptide of ApoB (Table 1) in approximately 
50 % of the protein population (not shown). Then, since the LDLR ligand was lost in 245 
this protein fraction the concentration of this construct was adjusted in further 
experiments to manage a comparative amount of full-length protein. However, in the 
insoluble cell fraction, the full length ApoB-GFP-H6 was detected as a unique protein 
band (Figure 1B). Mass spectrometry analysis demonstrated that the insoluble protein 
version showed the predicted molecular mass corresponding to the intact construct. In 250 
vitro refolding of ApoB-GFP-H6 IBs rendered homogeneous soluble protein 
preparations.   
 
Table 1. Amino acid sequences of protein ligands and known or putative targets. 
  255 
Ligand Aa sequence Target References 
Angiopep-2 TFFYGGSRGKRNNFKTEEY VLDLR (Demeule et 
al., 2008) 
Seq-1 KYLAYPDSVHIW N/A (Maggie, 
2011) 
ApoB SSVIDALQYKLEGTTRLTRKRGLKLA
TALSLSNKFVEGS 
LDLR (Spencer 
and Verma, 
2007a) 
VLDLR: Very-low-density-lipoprotein receptor 
N/A: Not available but a LDLR family member 
LDLR: Low density lipoprotein receptor 
Bold amino acid letter: first amino acid detected in the short ApoB form in the soluble cell fraction 
 260 
In a preliminary screening (Unzueta et al., 2012), Angiopep-2 and Seq-1 were 
observed as unable to promote the assembling of the fusion proteins in higher order 
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nanoparticles, probably due to their low cationic amino acid content, although doubts 
remained about the potential influence of the composition of the different buffers used 
to store the proteins. All the proteins produced here were tested again for nanoparticle 265 
formation under homogeneous buffer conditions as described above, in 166 mM 
NaHCO3, pH 7.4. The exclusive occurrence of unassembled forms of Seq-1-GFP-H6 
and Angiopep-2-GFP-H6 was indeed confirmed (Figure 2A), with a particle size, 
determined by DLS, compatible with that of GFP monomers or dimers (as GFP 
naturally tends to dimerization). Contrarily, ApoB-GFP-H6 formed nanoparticles in both 270 
its natural soluble form directly obtained from recombinant bacteria (ApoB-GFP-H6s), 
or when refolded in vitro from IBs (ApoB-GFP-H6IBs) (Figure 2A). However, ApoB-
GFP-H6s nanoparticles appeared to be unstable, as they peaked at 28 nm but also 
over 100 nm, indicative of aggregation. ApoB-GFP-H6IBs nanoparticles, instead, 
showed a unique monodisperse peak at 18 nm (Figure 2A), compatible with the 275 
formation of robust supramolecular structures. The aggregation of ApoB-GFP-H6s 
suspected in DLS measures was clearly confirmed by TEM, since amorphous protein 
clusters abounded in the fields (Figure 2B). This was in contrast with the highly regular 
architecture observed in 18 nm-ApoB-GFP-H6IBs particles (Figure 2B). Interestingly, 
all recombinant proteins retained GFP fluorescence (Figure 2C), with only moderate 280 
reduction in the case of Angiopep-2-GFP-H6 and ApoB-GFP-H6IBs. Importantly, the 
preservation of fluorescence emission allowed further characterization of the 
constructs’ biological properties by fluorescence analysis and imaging. 
 
In this regard, we first wanted to explore cell penetrability of all constructs in cells 285 
displaying and not displaying LDLRs. Uptake of protein constructs in LDLR- HUVEC 
was indeed negligible when comparing with that of closely related nanoparticles 
empowered by the unspecific but highly efficient cell penetrating peptide R9 (nine 
sequential arginines, (Vazquez et al., 2010)) (Figure 3A). In contrast, penetrability was 
highly stimulated in LDLR+ HeLa cells (Figure 3B), especially in the case of ApoB-GFP-290 
H6IBs. In presence of chloroquine, internalization of ApoB-GFP-H6IBs protein in HeLa 
cell population dramatically increased (Figure 4), indicative of an endosomal route as 
expected for any receptor-mediated uptake (Vazquez et al., 2008). Interestingly, the 
penetrability of ApoB-GFP-H6s was always lower than that of ApoB-GFP-H6IBs. This 
fact suggests that an unstable nanoparticle might be less suitable for proper receptor 295 
binding and cell internalization. Alternatively, the folding status of the protein (probably 
different as derived from the soluble cell fraction or from refolding) might influence 
ligand exposure and/or particle performance in a biologically significant way. The 
efficient cell penetration of ApoB-GFP-H6IBs was fully confirmed by confocal 
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microscopy (Figure 5). In general, the unassembled constructs were internalized by 300 
cells in a less efficient way, and the uptake was not influenced by background protein 
precipitation in the extracellular medium that has been generally observed in GFP-
based self-assembling proteins (Vazquez et al., 2010). 
 
Considering these cell internalization results, the transepithelial crossing efficiency of 305 
the LDLR-ligand functionalized modular proteins was determined in a fully stablished in 
vitro BBB model based on CaCo2 cells (Hellinger et al 2012) (Table 2). In the two 
protein concentrations tested, ApoB-GFP-H6IBs presented the highest penetrability in 
accordance with the internalization assays presented above (Figure 3). Angiopep-2-
GFP-H6 and Seq-1-GFP-H6 also displayed minor but still important penetrability in this 310 
BBB model at high protein concentration, thus suggesting a potential to effectively 
cross the BBB. However, when ApoB-GFP-H6s was challenged to the CaCo2 cell 
barrier, the apparent permeability was even lower than the negative control GFP, again 
indicating a failure of these protein nanoparticles to reach a fully functional status. 
Indeed, the stability of the Caco2 cell monolayer is shown in the data related to Papp of 315 
one the protein constructs (ApoB-GFP-H6s) at both protein concentrations maintained 
low through the experiment.  
 
Table 2. In vitro transepithelial crossing activity of BBB-targeted GFP proteins 
 320 
Protein Concentration 
(μM) 
Papp 
(cm/s)x10-6 
Angiopep-2-GFP-H6 
 
2 
10 
0.41±0.006 
16.6±1.5 
Seq-1-GFP-H6 
 
2 
10 
2.58±0.18 
9.75±0.004 
ApoB-GFP-H6s 2 
10 
0.21±0.09 
0.79±0.09 
ApoB-GFP-H6IBs 2 
10 
12.46±1.03 
18.02±4.79 
GFP 2 
10 
0.69±0.08 
2.41±0.44 
 
In a step further, and particularly encouraged by the good performance of ApoB-GFP-
H6IBs nanoparticles we wanted to examine the biodistribution of the protein set and the 
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potential influence of the supramolecular protein organization, upon systemic 
administration through the tail vein in healthy mice in which side events that affect brain 325 
permeability such as enhanced permeability and retention (EPR) effect do not take 
place. We were specifically interested in this issue as at one side, LDLR are important 
targets in BBB-crossing for drug delivery into the CNS (Demeule et al., 2008; Kim et 
al., 2007; Spencer and Verma, 2007b), and also, cationic protein nanoparticles are 
biocompatible materials that fulfil most of the requests posed for vehicle-mediated drug 330 
delivery into brain (Juillerat-Jeanneret, 2008). Therefore, we analysed ex vivo the 
signal from the whole brain to avoid the noise coming form the background of the 
whole body imaging followed by ex vivo recording of brain sagittal sections to complete 
evaluation of the extent of the emitted fluorescence. The analyses of these samples 
clearly indicated BBB-crossing properties of Angiopep-2-GFP-H6 and Seq-1-GFP-H6 335 
(Figure 6A). Angiopep-2-GFP-H6, in particular, was observed as accummulating in the 
brain parenchyma 30 min after administration, a fact that was fully assesed by 
quantitative analysis of fluorescence under conditions that not allowed GFP-H6 
background signal (Figure 6B,C). Surprisingly, ApoB-GFP-H6s but also ApoB-GFP-
H6IBs failed to accummulate into brain (Figure 6), indicating that the ApoB ligand was 340 
unable to drive the crossing of BBB under the presentation offered by the resulting 
nanoparticles.  
 
To understand better the stability in circulation and the potential renal clearance of both 
BBB-crossing and failing constructs, GFP fluorescence was also determined in kidney. 345 
All the constructs that did not form nanoparticles (namely Angiopep-2-GFP-H6 and 
Seq-1-GFP-H6, and the parental GFP-H6) and also the unstable ApoB-GFP-H6s 
nanoparticles accummulated in kidney (Figure 7A, B), indicative of renal clearance and 
consequently, of a material size under 8 nm (Cespedes et al., 2014). This is in 
agreement with the unability of Angiopep-2-GFP-H6 and Seq-1-GFP-H6 to self-350 
assemble, and it also suggests that the ApoB-GFP-H6s nanoparticles, observed in vivo 
as unstable, probably dissasamble once in the bloodstream (maybe due to the high salt 
content of the biological fluid). No fluorescence was recorded in lung and liver, in any 
case (not shown). 
 355 
These data indicates that a nanoparticulated architecture of ligand-containing proteins, 
promoting efficient cell penetrability and transcytosis, is neither sufficient nor necessary 
to reach the brain under systemic administration, and that unassembled soluble 
proteins, even when undergoing an effective renal clearance, are able to cross the BBB 
in a significant fraction.  360 
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Discussion 
Proteins are excellent functional carriers for therapeutic nucleic acids and conventional 
drugs (Aris and Villaverde, 2004; Nehate et al., 2014). When fused to the amino 
terminus of a His tagged GFP, the cationic peptide ApoB promotes the formation of 
nanoparticles that are only composed by the modular protein acting as self-interacting 365 
building block. This is based on a recently proposed protein engineering principle that 
allows designing protein nanoparticles by the fusion of cationic peptides to polyhistidine 
tagged polypeptides, and that act irrespective of the nature and sequence of the core 
protein (Cespedes et al., 2014; Unzueta et al., 2012). Nanoparticle formation is 
promoted by the hydrostatic contacts between the resulting dipolar monomers, but the 370 
whole supramolecular structure is largely stabilized by additional forces such as Van 
der Waals, hydrogen bond interactions (Cespedes et al., 2014; Unzueta et al., 2014), 
and protein-DNA interactions if used as non-viral gene therapy vehicle (Unzueta et al., 
2014). Interestingly, the amino terminal cationic peptide (ApoB in case of the current 
study) acts as an architectonic tag but also as a LDLR ligand with known BBB-crossing 375 
properties (see Table 1). Under the same conditions, the less cationic Seq-1 and 
Angiopep-2 peptides, also LDLR ligands, fail in promoting nanoparticle formation 
(Figure 2).  
 
On the other hand, ApoB-GFP-H6 nanoparticles have been obtained from two 380 
alternative protein sources, namely the soluble E. coli cell fraction (ApoB-GFP-H6s) or 
by in vitro refolding of purified ApoB-GFP-H6 IBs (ApoB-GFP-H6IBs). Although both 
protein versions act as self-organizing building blocks (Figure 2), ApoB-GFP-H6s 
nanoparticles are poorly stable as determined by DLS and by TEM (Figure 2). Then, 
the protein was found in kidney soon upon administration (Figure 7). Renal clearance 385 
was also observed in the parental GFP-H6 and in the unassembled Seq-1-GFP-H6 and 
Angiopep-2-GFP-H6 (Figure 7). In contrast, the robust ApoB-GFP-H6IBs particles with 
a regular size of 18 nm were not cleared by kidney, what necessarily results in a 
prolonged and stable circulation of the protein in the bloodstream. The time extended 
occurrence of ApoB-GFP-H6s in kidney 2 h after administration, not observed in any 390 
strictly monomeric protein (namely GFP-H6, Seg-1-GFP-H6 and Angiopep-2-GFP-H6, 
Figure 7), could be indicative of a progressive disassembling of the nanoparticles once 
in the bloodstream, and of a dynamic balance between assembled and disassembled 
forms. This would favor again the hypothesis of the intrinsic architectonic instability of 
ApoB-GFP-H6s particles. The differences in the stability of ApoB-GFP-H6IBs and 395 
ApoB-GFP-H6s, and also the differential cell penetrability of these constructs (Figure 
3B, 4, 5), can be only attributed to different conformations of the protein as resulting 
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from either the soluble cell fraction or from refolding from protein aggregates. For 
instance, the ApoB tail in ApoB-GFP-H6s might be more involved in crossmolecular 
contacts between building blocks and less available for cellular interactions. Of course, 400 
the heterogeneity in protein bands detected in the Western blot analysis of the soluble 
E. coli cell fraction, probably resulting from selective proteolysis (Figure 1B), could also 
contribute to this fact. Therefore, the conformational and structural status of protein 
building blocks of de novo designed nanoparticles, and the influence of the cell factory 
in the quality and properties of the final supramolecular assemblies is a currently 405 
neglected field that deserves deeper exploration (Ferrer-Miralles et al., 2013). This is 
especially relevant in the context of emerging biomaterials resulting from in vivo 
fabrication (Vazquez and Villaverde, 2013), the rising number of conventional and non-
conventional cell factories for protein and polymer production (Corchero et al., 2013; 
Ferrer-Miralles and Villaverde, 2013) and the new bio-engineering strategies to 410 
improve microbial biosynthesis regarding industrial and biopharma applications (Chen, 
2012; Lee et al., 2012; Rodriguez-Carmona and Villaverde, 2010). 
 
On the other hand, ApoB-GFP-H6IBs nanoparticles internalized cultured cells more 
efficiently than ApoB-GFP-H6s nanoparticle versions and than Seq-1-GFP-H6 and 415 
Angiopep-2-GFP-H6 proteins (Figure 3B, 5). The penetration of ApoB-GFP-H6IBs took 
place, as expected, in LDLR+ cells but not in LDLR- cells (Figure 3A). The control R9-
GFP-H6 nanoparticles, which are empowered by a potent Tat-inspired unspecific cell 
penetrating peptide (R9), do not shown any LDLR-linked preference in internalization 
(Figure 3). LDLR-dependent internalization is dramatically enhanced by chloroquine 420 
(Figure 4), indicative of an endosomal pathway. Under these conditions, ApoB-GFP-
H6IBs but no other constructs was essentially found in all cells among the population 
exposed to the nanoparticle, even when applied at moderate doses (1 µM). 
 
Although based on the good performance in in vitro experiments, ApoB-GFP-H6IBs 425 
particles were highly promising regarding BBB-crossing, none ApoB-derived protein 
version was found in the brain parenchyma up to two hours after iv administration 
(Figure 6). Surprisingly, Seq-1-GFP-H6 and Angiopep-2-GFP-H6 proteins were 
detected in brain in ex vivo imaging, with an occurrence that peaked at around 30 min. 
BBB-crossing of these two proteins occurred even with important renal filtration (Figure 430 
7), while skipping renal clearance did not promoted, by itself, brain localization of 
ApoB-derivatives. Being ApoB a well-known BBB-crossing peptide for soluble drugs 
(Kreuter et al., 2002b) and also when linked to nanoparticles (Kim et al., 2007), failure 
in a proper activity when empowering protein nanoparticles might be due to 
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inappropriate presentation of the ligand in these kind of constructs. In fact, due to its 435 
cationic nature, ApoB acts as both architectonic and targeting agent with limited solvent 
exposure when compared to ligands in monomeric proteins. Although such a dual 
activity is not by itself an obstacle for proper biodistribution of protein nanoparticles (as 
exemplified by the peptide T22 in similar GFP-based constructs) (Cespedes et al., 
2014; Unzueta et al., 2012) and also for ligand-mediated cell penetrability (Figure 3 and 440 
4), the most complex biological barriers imposed by brain vessels might represent a 
tighter bottleneck to proper biodistribution. 
 
Conclusions 
The results presented here upon exploration of three recombinant protein-only LDLR 445 
ligands, presented in a total of four versions, reveal that high cellular penetrability in 
cultured cells does not guarantee efficient BBB-crossing and brain targeting mediated 
by transcytosis-associated receptors. Interestingly, protein versions in form of 
nanoparticles do penetrate cultured cells more efficiently than unassembled constructs, 
while the contrary is true regarding in vivo BBB-crossing. Such a divergent 450 
performance prompts to evaluate the use of nanoparticulate materials for BBB-crossing 
therapies, which even being highly efficient in cell culture might find in vivo bottlenecks 
essentially distinguishable from those encountered when aiming to targets other than 
brain. 
 16 
 455 
LEGENDS 
 
 
Figure 1. Structure of the fusion proteins. A) EGFP was used as the core of the fusions 
(green), flanked by a cell ligand at the N-terminus (blue) and a hexahistidine at the C-460 
terminus (brown). A linker segment (orange) was placed between the ligand and GFP. 
Residues in green indicate the end terminal amino acids of GFP in the joining regions. 
The sequences of the fused N-terminal ligands are depicted in Table 1. B) Western blot 
analyses of disrupted bacteria producing the different fusion proteins, upon fractioning. 
 465 
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Figure 2. Characterization of proteins and protein nanoparticles. A) Size distribution of 
purified proteins, determined by DLS. Pdi is polydispersion index. B) TEM analyses of 
two versions of ApoB-GFP-H6, namely straightforward soluble protein or protein 
species refolded from IBs. C) Specific fluorescence emission of all protein versions, 470 
compared to that of commercial, control GFP. 
 18 
 
Figure 3. Internalization of proteins and protein nanoparticles. Cell penetrability was 
determined by both total fluorescence emission (left) and by the fraction of fluorescent 
cells (right). Targets were LDLR- HUVEC (A) and LDLR+ HeLa (B) cells. Proteins were 475 
added to the cultures at two alterative concentrations, namely 1 and 9 µM. Those 
proteins showing significant differences with GFP-H6 are labelled with asterisks (**, 
p<0.01; *, p<0.05). 
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Figure 4. Endosomal escape of proteins and protein nanoparticles. Cell penetrability 
was determined by both total fluorescence emission (left) and by the fraction of 
fluorescent cells (right). Data have been obtained in LDLR+ HeLa cells in presence of 
chloroquine. Those proteins showing significant differences with GFP-H6 are labelled 485 
with asterisks (**, p<0.01; *, p<0.05). Note the differences in the Y scale when 
comparing to Figure 3. 
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 490 
Figure 5. Internalization of proteins and protein nanoparticles monitored by confocal 
microscopy in HeLa cells. The white bars indicate 15 µm. A magnified inset of ApoB-
GFP-H6IBs has been included to stress the nanoparticulate nature of the internalized 
material (arrows), despite some extracellular protein precipitation. Nuclei are labeled in 
blue and cell membranes in red. 495 
 21 
 
 
Figure 6. Biodistribution of proteins and protein nanoparticles in ex vivo imaging. GFP 
fluorescence registered ex vivo in mouse whole brain (W) and sagittal sections (S) at 
30 minutes and 2 hours after iv administration of 500 μg of each protein. Black arrows 500 
show fluorescence signal accumulation in the brain parenchyma (A). Quantitative 
determination of GFP ﬂuorescence analyzed in whole brain (B) and sagittal sections 
(C) expressed as the total radiant efficiency (photon/s/cm2/sr/μW/cm2). Those proteins 
showing significant differences with the rest of proteins are labelled with asterisks (**, 
p<0.01; *, p<0.05). Data from 30 min and 2 h samples have been compared 505 
separately. 
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Figure 7. Renal clearance of protein nanoparticles in ex vivo imaging. GFP 510 
ﬂuorescence registered ex vivo in mouse kidneys 30 minutes and 2 hours after iv 
administration of 500 μg of each construct (A). Quantitative determination of GFP 
ﬂuorescence expressed as the total radiant efficiency (photon/s/cm2/sr/μW/cm2) 
(B). Those proteins showing significant differences with the rest of proteins are labelled 
with asterisks (**, p<0.01; *, p<0.05). Data from 30 min and 2 h samples have been 515 
compared separately. 
 
 
 
 520 
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